SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)

6/10/22 11:04:56 AM ET

Agricultural Chemicals

Industrials

Get the next $CLXT alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 CALYXT INC COMMON STOCK Cusip #13173L107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #13173L107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 573,295 Item 6: 0 Item 7: 573,295 Item 8: 0 Item 9: 573,295 Item 11: 1.340% Item 12: HC Cusip #13173L107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 573,295 Item 8: 0 Item 9: 573,295 Item 11: 1.340% Item 12: IN Item 1(a). Name of Issuer: CALYXT INC Item 1(b). Address of Issuer's Principal Executive Offices: 2800 MOUNT RIDGE ROAD ROSEVILLE, MN 55113 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 13173L107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 573,295 (b) Percent of Class: 1.340% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 573,295 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CALYXT INC. No one other person's interest in the COMMON STOCK of CALYXT INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. June 9, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on June 9, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CALYXT INC at May 31, 2022. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $CLXT alert in real time by email

Date

Price Target

Rating

Analyst

3/4/2022

$6.00 → $4.00

Buy

Canaccord Genuity

11/2/2021

$10.00

Buy

ROTH Capital

SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$CLXT

$CLXT
Press Releases

Fastest customizable press release news feed in the world

Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

Calyxt Announces Stockholder Approval of Merger With Cibus

Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

$CLXT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

$CLXT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)

Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

SEC Form 3: New insider Collins James C. Jr. claimed no ownership of stock in the company

$CLXT
Financials

Live finance-specific insights

$CLXT
Leadership Updates

Live Leadership Updates

Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time

Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

Calyxt Names IBM's Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Scientific Advisory Board

Calyxt Appoints Michael A. Carr as Chief Executive Officer

$CLXT
SEC Filings

Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

SEC Form 424B5 filed by Calyxt Inc.

$CLXT
Large Ownership Changes

This live feed shows all institutional transactions in real time.